Chinese Community Sample of Hierarchical Model of Psychopathology

Chinese Community Sample of Hierarchical Model of Psychopathology : Validation and Analysis of Underline Trans-diagnostic Risk Factors

By validating Hierarchy Model of psychopathology(HiTOP) in Chinese community samples, this study aims for illumating the problem of diagnostic heterogeneity and high comorbidity within existing psychiatric classification systems in Chinese culture. Concurrently, this study also focuses on exploring trans-diagonostic risk and proctective factors underline HiTOP dimensions.

the main questions it aims to answer are:

1. Explore HiTOP model cultural differences between western culture and eastern culture.
2. Understand the impact of different dimension of adverse childhood experience on HiTOP structure.
3. Investigate the relationship between individual unique psychological variables and psychopathological dimensions.

Participants will receive a detailed survey trying to measure their psychopathology symptoms, adverse childhood experience and psychological variables. This study expects to fallow up participants for 4 years to monitor the symptom changes.

Study Overview

• Status: Recruiting
• Conditions: Mental Health Issue; Adverse Childhood Experience
• Intervention / Treatment: Other: No intervention

• Study Type: Observational
• Enrollment (Estimated): 4000

Contacts and Locations

• Study Contact: Name: Zhen Wang, Phd, MD; Phone Number: +8634773516; Email: wangzhen@smhc.org.cn

Study Locations

• China
  • Shanghai, China
    • Recruiting
    • Shanghai Mental Health Center
    • Contact: Zhen Wang, MD,PhD; Phone Number: 73516 862164387259; Email: wangzhen@smhc.org.cn
    • Principal Investigator: Zhen Wang, MD,PhD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

• Sampling Method: Probability Sample

Study Population

This study aims to recruits partcipants across the whole regions of China, with the aim of collecting representative Chinese community sample.

Description

Inclusion Criteria:

1. Chinese citizens
2. Years of education > =9 years.
3. age >= 18 years old.

Exclusion Criteria:

(1)Subjects who have insufficient self-awareness, and are unable to obtain complete informed consent, such as: schizophrenia, manic episode of bipolar disorder, severe depression.

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Community sample; Using social media to randomly inviting participants across all regions of China.	Other: No intervention; cross sectional study#no intervention

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Chinese version of Hierarchy Model of psychopathology	Constructing the Chinese version of Hierarchy Model of psychopathology. Comparing the differences between Chinese version and western version.	1 year
Mapping different dimension of adverse childhood experience on Hierarchy Model of psychopathology structure		1 year

Secondary Outcome Measures

Outcome Measure	Time Frame
Investigate the relationship between individual unique psychological variables and psychopathological dimensions.	4 years

Collaborators and Investigators

• Sponsor: Shanghai Mental Health Center
• Investigators: Principal Investigator: Zhen Wang, PhD, MD, Shanghai Mental Health Center

Study record dates

Study Major Dates

• Study Start (Actual): September 26, 2023
• Primary Completion (Estimated): November 1, 2023
• Study Completion (Estimated): November 1, 2027

Study Registration Dates

• First Submitted: October 24, 2023
• First Submitted That Met QC Criteria: October 24, 2023
• First Posted (Actual): October 30, 2023

Study Record Updates

• Last Update Posted (Actual): October 30, 2023
• Last Update Submitted That Met QC Criteria: October 24, 2023
• Last Verified: October 1, 2023

More Information

Terms related to this study

• Keywords: Hierarchical Model of Psychopathology
• Other Study ID Numbers: HiTOP001

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No